Nuvo Research completes phase 2 study of WF10 for treatment of allergic rhinitis

Nuvo Research Inc. has completed a phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis, according to a press release.

One of the main purposes of the study was to validate the results of Nuvo Research’s 60-patient phase 2 proof-of-concept clinical trial conducted in 2010, Henrich Guntermann, MD, MSc, president of the Europe & Immunology Group at Nuvo Research Inc., said in the release.

WF10 is composed of stabilized chlorite ions that target white blood cells to balance the immune system, according to the release.

The ongoing phase 2, 16-week clinical trial included 179 participants and was a randomized, double-blind, placebo-controlled study that looked at the safety and tolerability of five IV infusions of WF10 in patients with refractory allergic rhinitis with sensitivities to multiple airborne allergens. The trial began in March 2014 at 15 sites across Germany. In the study, researchers measured total nasal symptom score, total ocular symptom score and other secondary endpoints.

“Patients in that study and in independent case studies have reported that a single 5-day course of treatment with WF10 could provide one to two years of symptomatic relief from multiple airborne allergens,” he said in the release. “These unique attributes make WF10 a revolutionary product candidate for patients who don’t obtain adequate relief from standard allergy treatments such as antihistamines and inhaled corticosteroids.”

Nuvo Research expects to release the results of the study in mid-February of 2015.